



03-24-04

TRANSMITTAL
FORM

Application Serial Number	10/603,064
Filing Date	June 24, 2003
First Named Inventor	Gillies
Group Art Unit	1646
Examiner Name	Mertz, P.
Attorney Docket No.	LEX-010C1
Confirmation No.	8576
Patent No.	Not applicable
Issue Date	Not applicable

ENCLOSURES (check all that apply)

- | | | |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form (1 pg.)
<input type="checkbox"/> Check Attached
<input type="checkbox"/> Copy of Fee Transmittal Form

<input type="checkbox"/> Amendment
<input type="checkbox"/> Supplemental Preliminary
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets]

<input type="checkbox"/> Petition for Extension of Time

<input checked="" type="checkbox"/> Information Disclosure Statement
<input checked="" type="checkbox"/> Form PTO-1449
<input checked="" type="checkbox"/> Copies of IDS Citations (A41-A82; B58-B80; and C108-C195)

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Sequence Listing submission
<input type="checkbox"/> Paper Copy/CD
<input type="checkbox"/> Computer Readable Copy
<input type="checkbox"/> Statement verifying identity of above | <input type="checkbox"/> Copy of the Notice to File Missing Parts

<input type="checkbox"/> Formal Drawing(s)

<input type="checkbox"/> Request For Continued Examination (RCE) Transmittal

<input type="checkbox"/> Declaration and Power of Attorney

<input type="checkbox"/> Terminal Disclaimer

<input type="checkbox"/> Copy of the executed Declaration and Power of Attorney for Utility or Design Patent Application

<input type="checkbox"/> Small Entity Statement

<input type="checkbox"/> CD(s) for large table or computer program

<input type="checkbox"/> Amendment After Allowance

<input type="checkbox"/> Request for Certificate of Correction
<input type="checkbox"/> Certificate of Correction (in duplicate) | <input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences

<input type="checkbox"/> Appeal Brief (in triplicate)

<input type="checkbox"/> Status Inquiry

<input checked="" type="checkbox"/> Return Receipt Postcard

<input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8

<input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8


<input type="checkbox"/> Additional Enclosure(s) (please identify below) |
|---|---|--|

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,


Date: March 23, 2004
Reg. No. 48,645
Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100
Brian A. Fairchild, Ph.D.
Attorney for the Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110



PATENT
Attorney Docket No. LEX-010C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Gillies *et al.*
SERIAL NO.: 10/603,064 GROUP NO.: 1646
FILING DATE: June 24, 2003 EXAMINER: Mertz, P.
TITLE: MULTIPLE CYTOKINE PROTEIN COMPLEXES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying copies of Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. References AA-A40, BA-B57 and CA-C107 were previously cited and made of record in parent application 09/634,368, on which the present application relies for an effective filing date under 35 U.S.C. § 120. As permitted under 37 C.F.R. § 1.98(d), copies of references AA-A40, BA-B57 and CA-C107 are not provided herewith.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Applicants believe no fee is necessitated by this submission. If a fee is due, please debit deposit account 20-0531.

Respectfully submitted,



Brian A. Fairchild, Ph.D.

Attorney for Applicant

Testa, Hurwitz, & Thibault, LLP


High Street Tower

125 High Street

Boston, Massachusetts 02110

Date: March 23, 2004
Reg. No. 48,645

Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.: LEX-010C1

APPLICANT: Gillies et al.

SERIAL NO.: 10/603,064

FILING DATE: June 24, 2003

GROUP: 1653

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,314,995	5-24-94	Fell, Jr. et al.	530	351	1-22-90
	AB	5,114,711	5-19-92	Bell et al.	424	85.1	7-13-89
	AC	5,073,627	12-17-91	Curtis et al.	530	351	8-14-90
	AD	4,946,778	8-7-90	Ladner et al.	435	69.6	
	AE	4,676,980	6-30-87	Segal et al.	424	85	9-23-85
	AF	4,469,797	9-4-84	Albarella	436	536	9-23-82
	AG	4,196,265	4-1-80	Koprowski et al.	435	2	8-11-78
	AH	5,650,150	7-22-97	Gillies	424	134.1	7-27-94
	AI	5,541,087	6-30-96	Lo et al.	435	697	9-14-94
	AJ	5,726,044	3-10-98	Lo et al.	435	69.7	9-14-95
	AK	5,843,423	12-1-98	Lyman et al.	424	85.1	12-18-97
	AL	5,858,347	1-12-99	Bauer et al.	424	85.2	6-6-95
	AM	5,908,626	6-1-99	Chang et al.	424	134.1	12-19-97
	AN	5,199,942	4-6-93	Gillis	604	4	9-26-91
	AO	07/348,237		Rosenblum et al.			5-5-89
	A1	4,816,567	3/28/89	Cabilly et al.	530	387	
	A2	5,116,964	5/26/92	Capon et al.	536	27	
	A3	5,225,538	7/6/93	Capon et al.	530	387.3	
	A4	5,225,539	7/6/93	Winter	530	387.3	
	A5	5,258,498	11/2/93	Huston et al..	530	350.0	
	A6	5,349,053	9/20/94	Landolfi	530	351	
	A7	5,514,582	5/7/96	Capon et al.	435	252.3	
	A8	5,543,297	8/6/96	Cromlish, et al.	435	25	
	A9	5,552,524	09/03/96	Basinski et al.			
EXAMINER					DATE CONSIDERED		

FORM PTO - 1449				ATTY DOCKET NO.: LEX-010C1			
INFORMATION DISCLOSURE STATEMENT				APPLICANT: Gillies et al.			
				SERIAL NO.: 10/603,064			
				FILING DATE: June 24, 2003			
				GROUP: 1653			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A10	5,585,089	12/17/96	Queen et al.	424	133.1	
	A11	5,609,846	3/11/97	Goldenberg	424	1.41	
	A12	5,639,725	6/17/97	O'Reilly et al.	514	12	
	A13	5,650,492	7/22/97	Gately, et al.	530	351	
	A14	5,667,776	9/16/97	Zimmerman et al.	424	238	
	A15	5,691,309	11/25/97	Basinski et al.			
	A16	5,719,266	02/17/98	DiMarchi et al.			
	A17	5,723,125	3/3/98	Chang et al.	424	134.1	
	A18	5,726,044	3/10/98	Lo et al.			
	A19	5,728,552	3/17/98	Fujisawa et al.	435	69.5	
	A20	5,733,876	3/31/98	O'Reilly et al.	514	12	
	A21	5,756,461	05/26/98	Stephens			
	A22	5,759,551	6/2/98	Ladd et al.	424	198.1	
	A23	5,770,195	6/23/98	Hudziak et al.	424	130.1	
	A24	5,800,810	9/1/98	Doyle et al.	424	85.2	
	A25	5,827,516	10/27/98	Urban et al.	424	93.21	
	A26	5,837,682	11/17/98	Folkman et al.	514	12	
	A27	5,854,205	12/29/98	O'Reilly et al.	514	2	
	A28	5,885,795	3/23/99	O'Reilly et al.	435	69.1	
	A29	5,886,178	3/23/99	Allen et al.	544	238	
	A30	5,994,126	11/30/99	Steinman et al.	435	325	
	A31	6,080,409	6/27/00	Laus et al.	424	192.1	
	A32	6,086,875	7/11/00	Blumberg et al.	424	134.1	
	A33	6,169,070	1/2/01	Chen et al.			
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449				ATTY DOCKET NO.: LEX-010C1			
INFORMATION DISCLOSURE STATEMENT				APPLICANT: Gillies et al.			
				SERIAL NO.: 10/603,064			
				FILING DATE: June 24, 2003			
				GROUP: 1653			
U.S PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A34	6,171,588	1/9/01	Carron et al.			
	A35	6,100,387	8/8/00	Herrmann et al.			
	A36	5,359,035	10/25/94	Habermann			
	A37	5,645,835	7/8/97	Fell, Jr. et al.			
	A38	5,807,715	9/15/98	Morrison et al.			
	A39	5,922,685	7/13/99	Rakhmilevich et al.			
	A40	6,348,192	2/19/02	Chan et al.			
	A41	4,703,008	10/27/87	Lin			
	A42	5,019,368	5/28/91	Epstein et al.			
	A43	5,441,868	8/15/95	Lin			
	A44	5,457,038	10/10/95	Trinchieri et al.			
	A45	5,538,866	7/23/96	Israeli et al.			
	A46	5,547,933	8/20/96	Lin			
	A47	5,618,698	4/8/97	Lin			
	A48	5,624,821	4/29/97	Winter et al.			
	A49	5,679,543	10/21/97	Lawlis			
	A50	5,688,679	11/18/97	Powell			
	A51	5,709,859	1/20/98	Aruffo et al.			
	A52	5,756,349	5/26/98	Lin			
	A53	5,856,298	1/5/99	Strickland			
	A54	5,888,772	3/30/99	Okasinski et al.			
	A55	5,955,422	9/21/99	Lin			
	A56	6,231,536	5/15/01	Lentz			
	A57	6,277,375	8/21/01	Ward			
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449				ATTY DOCKET NO.: LEX-010C1			
INFORMATION DISCLOSURE STATEMENT				APPLICANT: Gillies et al.			
				SERIAL NO.: 10/603,064			
				FILING DATE: June 24, 2003			
				GROUP: 1653			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A58	6,284,536	9/4/01	Morrison et al.			
	A59	6,335,176	1/1/02	Inglese et al.			
	A60	6,340,742	1/22/02	Burg et al.			
	A61	6,406,689	6/18/02	Falkenberg et al.			
	A62	6,444,792	9/3/02	Gray et al.			
	A63	6,475,717	11/5/02	Enssle et al.			
	A64	6,485,726	11/26/02	Blumberg et al.			
	A65	6,506,405	1/14/03	Desai et al.			
	A66	6,583,272	6/24/03	Bailon			
	A67	6,586,398	7/1/03	Kinstler et al.			
	A68	6,617,135	9/9/03	Gillies et al.			
	A69	2001/0053539	12/20/01	Lauffer et al.			
	A70	2002/0081664	6/27/02	Lo et al.			
	A71	2002/0142374	10/3/02	Gallo et al.			
	A72	2002/0147311	10/10/02	Gillies et al.			
	A73	2002/0192222	12/19/02	Blumberg et al.			
	A74	2002/0193570	12/19/02	Gillies et al.			
	A75	2003/0003529	1/2/03	Bayer			
	A76	2003/0044423	3/6/03	Gillies et al.			
	A77	2003/0049227	3/13/03	Gillies et al.			
	A78	2003/0105294	6/5/03	Gillies et al.			
	A79	2003/0012789	1/6/03	Blumberg et al.			
	A80	2003/0157054	8/21/03	Gillies et al.			
	A81	2003/0166163	9/4/03	Gillies			
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449				ATTY DOCKET NO.: LEX-010C1					
INFORMATION DISCLOSURE STATEMENT				APPLICANT: Gillies et al.					
				SERIAL NO.: 10/603,064					
				FILING DATE: June 24, 2003					
				GROUP: 1653					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	A82	2003/0166877	9/4/03	Gillies et al.					
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
	BA	W091/14438	10-3-91	PCT			3-20-91		
	BB	W091/13166	09-05-91	PCT			1-30-91		
	BC	0 439 095 A2	7-31-91	EPO			1-21-91		
	BD	0 396 387 A2	11-7-90	EPO			5-1-90		
	BE	0 375 562	6-27-90	EPO					
	BF	W0 90/03801	4-19-90	PCT			10-11-89		
	BG	0 314 317 A1	5-3-89	EPO			10-3-88		
	BH	WO89/02922	4-6-89	PCT			10-3-88		
	BI	0 308 936 A2	3-29-89	EPO			9-22-88		
	BJ	WO88/09344	12-1-88	PCT			5-19-88		
	BK	0 294 703 A2	12-14-88	EPO			6-1-88		
	BL	WO88/00052	1-14-88	PCT			7-6-87		
	BM	WO86/01533	3-13-86	PCT			9-3-85		
	BN	0 158 198 A1	10-16-85	EPO			3-23-85		
	BO	WO93/10229	5-27-93	PCT			11-19-92		
	BP	WO97/24137	7-10-97	PCT			12-13-96		
	BQ	WO95/28427	10-26-95	PCT			4-15-94		
	BR	0 601 043 B1	11-25-98	EPO			8-24-92		
	BS	0 326 120 B1	4-15-98	EPO			1-25-89		
	BT	37 12985 A1	11-3-88	DE			4-16-87		
	BU	93100115.3	7-14-93	CN			2-6-93		
EXAMINER					DATE CONSIDERED				

FORM PTO - 1449					ATTY DOCKET NO.: LEX-010C1				
INFORMATION DISCLOSURE STATEMENT					APPLICANT: Gillies et al.				
					SERIAL NO.: 10/603,064				
					FILING DATE: June 24, 2003				
					GROUP: 1653				
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
	BV	87-56676	11-4-88	JP			3-13-87		
	BW	87-56677	11-4-88	JP			3-13-87		
	BX	WO00/11033	3-2-00	PCT			8-25-99		
	BY	WO00/40615	7-13-00	PCT			1-7-00		
	BZ	21725/88	3-23-89	AU			9-1-88		
	BBA	211769	2-25-87	EPO			8-7-86		
	BBB	319012	6-7-89	EPO			12-2-88		
	BBC	256714	2-24-88	EPO			7-30-87		
	BBD	350230	1-10-90	EPO			7-3-89		
	BBE	WO 88/09344	12-1-88	WO			5-19-88		
	BBF	WO 96/04388	02-15-96	WO			7-28-95		
	B1	WO 89/02922	4/6/89	PCT			10/3/88		Y
	B2	WO 89/09620	10/19/89	PCT				English Abstract	N
	B3	WO 91/00360	1/10/91	PCT			006		Y
	B4	WO 91/08298	6/13/91	PCT			006		Y
	B5	WO 92/02240	2/20/92	PCT					Y
	B6	WO 92/08495	5/29/92	PCT					Y
	B7	WO 92/08801	5/29/92	PCT			006		Y
	B8	WO 92/16562	10/1/92	PCT					Y
	B9	WO 93/03157	2/18/93	PCT			006		Y
	B10	WO 95/05468	2/23/95	PCT			002		Y
	B11	WO 95/21258	8/10/95	PCT			006		Y
	B12	WO 96/05309	2/22/96	PCT			008		Y
	B13	WO 96/08570	3/21/96	PCT			006		Y
EXAMINER					DATE CONSIDERED				

FORM PTO - 1449					ATTY DOCKET NO.: LEX-010C1				
INFORMATION DISCLOSURE STATEMENT					APPLICANT: Gillies et al. SERIAL NO.: 10/603,064 FILING DATE: June 24, 2003 GROUP: 1653				
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
	B14	WO 96/18412	6/20/96	PCT			002		Y
	B15	WO 96/31526	10/10/96	PCT			008		Y
	B16	WO 97/00317	9/18/97	PCT			003		Y
	B17	WO 97/00319	1/3/97	PCT			002		Y
	B18	WO 97/15666	5/1/97	PCT			004		Y
	B19	WO 97/20062	6/5/97	PCT			003		Y
	B20	WO 97/24440	7/10/97	PCT			008		Y
	B21	WO 97/26335	7/24/97	PCT			008		Y
	B22	WO 97/30089	8/21/97	PCT					Y
	B23	WO 97/33617	9/18/97	PCT			002		Y
	B24	WO 97/33619	1/3/97	PCT			003		Y
	B25	WO 97/34631	9/25/97	PCT			002		Y
	B26	WO 98/00127	1/8/98	PCT					Y
	B27	WO 98/06752	2/19/98	PCT			008		Y
	B28	WO 98/28427	7/2/98	PCT			008		Y
	B29	WO 98/30706	7/16/98	PCT			007		Y
	B30	WO 98/46257	10/98	PCT			008		Y
	B31	WO 99/43713	9/2/99	PCT					Y
	B32	WO 99/62944	12/09/99	PCT					Y
	B33	EP 0 294703A2		EP					Y
	B34	EP 0 314317 A1		EP					Y
	B35	EP 0 439 095 A2		EP					Y
	B36	EP 0 511 747	11/4/92	EP					Y
	B37	EP 0 706 799 A3	4/17/96	EP					Y
	B38	0 790 309 A1	8/20/97	EPO			002		Y
EXAMINER					DATE CONSIDERED				

FORM PTO - 1449					ATTY DOCKET NO.: LEX-010C1				
INFORMATION DISCLOSURE STATEMENT					APPLICANT: Gillies et al.				
					SERIAL NO.: 10/603,064				
					FILING DATE: June 24, 2003				
					GROUP: 1653				
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLIS H LANG Y/N
	B39	GB 2292382 A	2/21/96	GB					Y
	B40	WO 91/04329A1	04/04/91	PCT			08/01/90		Y
	B41	WO 00/69913A1	11/23/02	PCT			05/19/00		Y
	B42	WO 98/59244	12/30/98	PCT				N	Y
	B43	WO 99/02709	01/21/99	PCT				N	Y
	B44	WO 99/03887	01/28/99	PCT				N	Y
	B45	WO 00/34317	06/15/00	PCT				N	Y
	B46	WO 99/52562	10/21/99	PCT					Y
	B47	WO 99/29732	6/17/99	PCT					Y
	B48	WO 01/07081 A1	2/1/01	PCT					Y
	B49	WO 99/53958	10/28/99	PCT					Y
	B50	93100115.3	7/14/93	CN				English abstract of BU	Y
	B51	37 12985	11/3/88	DE				English abstract of BT A36 is English counter- part.	Y
	B52	63-267278	11/4/88	JP				English abstract of BW	Y
	B53	63-267296	11/4/88	JP				English abstract of BV	Y
	B54	0 237 019	9/16/87	EP				English counterpart of BV	Y
	B55	0 318 554 B1	4/5/95	EP					Y
	B56	WO 97/24440	7/10/97	PCT					Y
	B57	WO 99/60128	11/25/99	PCT					Y
	B58	0 640 619 A1	3/1/95	EP					Y
	B59	0 668 353 A1	8/23/95	EP					Y
EXAMINER					DATE CONSIDERED				

FORM PTO – 1449					ATTY DOCKET NO.: LEX-010C1				
INFORMATION DISCLOSURE STATEMENT					APPLICANT: Gillies et al.				
					SERIAL NO.: 10/603,064				
					FILING DATE: June 24, 2003				
					GROUP: 1653				
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILIN G DATE	ABSTRACT ONLY	ENGLIS H LANG Y/N
	B60	1 088 888 A1	4/4/01	EP					Y
	B61	WO 94/24160	10/27/94	PCT					Y
	B62	WO 94/25055	11/10/94	PCT					Y
	B63	WO 95/31483	11/23/95	PCT					Y
	B64	WO 97/43316	11/20/97	PCT					Y
	B65	WO 99/66054	12/23/99	PCT					Y
	B66	WO 00/24893	5/4/00	PCT					
	B67	WO 00/68376	11/16/00	PCT					Y
	B68	WO 00/78334	12/28/00	PCT					Y
	B69	WO 01/10912	2/15/01	PCT					Y
	B70	WO 01/36489	5/25/01	PCT					Y
	B71	WO 01/58957	8/16/01	PCT					
	B72	WO 02/02143	1/10/02	PCT					
	B73	WO 02/066514	8/29/02	PCT					Y
	B74	WO 02/072605	9/19/02	PCT					
	B75	WO 02/079232	10/10/02	PCT					
	B76	WO 02/079415	10/10/02	PCT					
	B77	WO 02/090566	11/14/02	PCT					
	B78	WO 03/015697	2/27/03	PCT					Y
	B79	WO 03/048334	6/12/03	PCT					
	B80	WO 03/077834	9/25/03	PCT					Y
EXAMINER					DATE CONSIDERED				

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003	
		GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	CA	Harris et al., "Therapeutic Antibodies - the Coming of Age" <u>Tibtech</u> , <u>11</u> :42-44 (Feb. 1993).	
	CB	Hoogenboom et al., <u>Biochim. and Biophys. Acta</u> , <u>1096</u> :345-354 (1991) (Abstract).	
	CC	Gillies et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities", <u>Hum. Antibod. Hybridomas</u> , <u>1</u> (No. 1):47-54 (1990).	
	CD	Shin et al., "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting.", <u>Proc. Natl. Acad. Sci. USA</u> , <u>87</u> :5322-5326 (1990).	
	CE	Capon et al., "Designing CD4 immunoadhesins for AIDS therapy", <u>Nature</u> , <u>337</u> :525-530 (1989).	
	CF	Gillies et al., "Expression of Human Anti-Tetanus toxoid antibody in Transfected Murine Myeloma Cells.", <u>Bio/Technology</u> , <u>7</u> :799-804 (1989).	
	CG	Gillies et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes", <u>J. Immuno. Methods</u> , <u>125</u> :191-202 (1989).	
	CH	Herrmann et al., "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor.", <u>J. Clin. Oncol.</u> , <u>7</u> (2):159-167 (1989).	
	CI	Pastan et al., "Pseudomonas Exotoxin: Chimeric Toxins", <u>J. Biol. Chem.</u> , <u>264</u> (No. 26):15157-15160 (1989).	
	CJ	Bacha et al., "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein", <u>J. Experimental Medicine</u> , <u>167</u> :612-622 (1988).	
	CK	Beutler et al., "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator", <u>Ann. Rev. Biochem.</u> , <u>57</u> :505-518 (1988).	
	CL	Chaudhary et al., "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein", <u>Nature</u> , <u>335</u> :369-372 (1988).	
	CM	Liu et al., "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells", <u>Science</u> , <u>239</u> :395-398 (1988).	
	CN	Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , <u>6</u> :407-438.	
	CO	Till et al., "HIV-Infected Cells are Killed by rCD4-Ricin A Chain", <u>Science</u> , <u>242</u> :1166-1168 (1988).	
	CP	Williams et al., "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein", <u>Protein Engineering</u> , <u>1</u> (No. 6):493-498 (1987).	
	CQ	Goeddel et al., "Tumor Necrosis Factors; Gene Structure and Biological Activities", pp. 597-609 (1986).	
EXAMINER		DATE CONSIDERED	

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003	
		GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	CR	Jung et al., "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates", <u>Proc. Natl. Acad. Sci. USA</u> , <u>83</u> :4479-4483 (1986).	
	CS	Murphy et al., "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α -melanocyte-stimulating hormone fusion protein", <u>Proc. Natl. Acad. Sci. USA</u> , <u>83</u> :8258-8262 (1986).	
	CT	Perez et al., "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies", <u>J. Experimental Medicine</u> , <u>163</u> :166-178 (1986).	
	CU	Santon et al., "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice", <u>Cancer Research</u> , <u>46</u> :4701-4705 (1986).	
	CV	Shen et al., "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG mediates cytotoxicity by Human Monocytes that is enhanced by interferon- λ and is not blocked by human IgG", <u>J. Immunology</u> <u>137</u> (No. 11):3378-3382 (1986).	
	CW	Henkart, "Mechanism of Lymphocyte-Mediated Cytotoxicity", <u>Ann. Rev. Immunol.</u> , <u>3</u> :31-58 (1985).	
	CX	Liu et al., "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , <u>82</u> :8648-8652 (1985).	
	CY	Nedwin et al., "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization", <u>Nucleic Acids Research</u> , <u>13</u> (No. 17):6361-6373 (1985).	
	CZ	Gasson et al., "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils", <u>Science</u> , <u>226</u> :1339-1339-1342 (1984).	
	CCA	Karpovsky et al., "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc γ Receptor Antibodies", <u>J. Experimental Medicine</u> , <u>160</u> :1686-1701 (1984).	
	CCB	Kranz et al., "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , <u>81</u> :7922-7926 (1984).	
	CCC	Neuberger, et al., "Recombinant Antibodies Possessing Novel Effector Functions.", <u>Nature</u> , <u>312</u> :604-608 (1984).	
	CCD	Taniguchi et al. (1983) <u>Macmillan Journals Ltd.</u> "Structure and expression of a cloned cDNA for human interleukin-2"	
	CCE	Williams et al., "Diphtheria Toxin Receptor Binding Domain Substitution with Interleukin-2 (Abstract).	
	CCF	Burgess et al., <u>J. of Cell Biol.</u> , <u>111</u> :2129-2138.	
	CCG	Lazar et al., <u>Molecular and Cellular Biology</u> , <u>8</u> :1247-1252.	
EXAMINER		DATE CONSIDERED	

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTY DOCKET NO.: LEX-010C1 APPLICANT: Gillies et al. SERIAL NO.: 10/603,064 FILING DATE: June 24, 2003 GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	CCH	Tao et al., <u>J. of Immunology</u> , 143:2595-2601.	
	CCI	Grimaldi et al., "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73:2081-2805 (1989).	
	CCJ	Chang et al., <u>Seminars in Surgical Oncology</u> , 5:285-90 (1989).	
	CCK	Rosenberg, <u>Immunology Today</u> , 9:58-62 (1988).	
	CCL	Schnee et al., <u>Proc. Natl. Acad. Sci. USA</u> , 84:6904-6908 (1987).	
	CCM	Chaudhary et al., <u>Nature</u> , 339:394-397 (1989).	
	CCN	Williams et al., <u>Gene</u> , 43:319-324 (1986).	
	CCO	Murphy, "Immunotoxins", <u>Kluwer Academic Publishers</u> , 123-140 (1988).	
	CCP	Bjorn et al., <u>Cancer Research</u> , 45:1214-1221 (1985).	
	CCQ	Till et al., <u>Cancer Research</u> , 48:1119-1123 (1988).	
	CCR	Fell et al., <u>The J. of Immunology</u> , 146:2446-2452 (1991).	
	CCS	Hellstrom et al., <u>Proc. Natl. Acad. Sci USA</u> , 83:7059-7063 (1986).	
	CCT	Senter et al., <u>Proc. Natl. Acad. Sci USA</u> , 85:4842-4846 (1988).	
	C1	Abaza et al. <u>Journal of Protein Chemistry</u> , 11(5):433-444, 1992.	
	C2	Abstract XP-002116766, "Prostaglandins, their inhibitors and cancer" from Prostaglandins, Leukotrienes and Essential Fatty Acids (1996) 54(2):83-94.	
	C3	Arenberg et al. (1996) "Interferon- γ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> 184:981-992.	
	C4	Bachelot et al., "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo", <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , Vol. 39, March 1998, p. 271, Abstract #1856.	
	C5	Barnett et al. (1994) "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.	
	C6	Batova et al., "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5: 4259-4263 (1999).	
EXAMINER		DATE CONSIDERED	

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTY DOCKET NO.: LEX-010C1 APPLICANT: Gillies et al. SERIAL NO.: 10/603,064 FILING DATE: June 24, 2003 GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C7	Becker et al., "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707 (1996).	
	C8	Boehm et al. (1997) "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," Letters to Nature 390:404-407.	
	C9	Boehm et al. (1998) "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," Biochemical and Biophysical Research Communications 252:190-194.	
	C10	Brooks et al. (1994) "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," Cell 79:1157-1164.	
	C11	Canfield et al. (1991) "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," J. Exp. Med. 173: 1483-1491	
	C12	Cao et al. (1996) "Kringles Domains of Human Angiostatin," The Journal of Biological Chemistry 271(46):29461-29467.	
	C13	Cao et al. (1997) "Kringles 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," The Journal of Biological Chemistry 272(36):22924-22928.	
	C14	Chan et al. "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," J. Exp. Med. 173: 869-879 (1991)	
	C15	Chen et al., "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," J. Immunol. 159: 351-358 (1997).	
	C16	Cheon et al. (1994) "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," Proc. Natl. Acad. Sci. USA 91: 989-993.	
	C17	Cohen, S. L. et al., "Human leptin characterization," Nature, Vol. 382, p. 589. (August 15, 1996).	
	C18	Cole et al. (1997) "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," J. of Immunology, 3613-3621.	
	C19	Colombo et al. "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," Cancer Res. 56: 2531-2534 (1996)	
	C20	D'Amato et al. (1994) "Thalidomide is an inhibitor of angiogenesis," Proc. Natl. Acad. Sci. USA 91:4082-4085.	
	C21	D'Andrea et al. "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," J. Exp. Med. 176: 1387-1398 (1992)	
EXAMINER		DATE CONSIDERED	

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTY DOCKET NO.: LEX-010C1 APPLICANT: Gillies et al. SERIAL NO.: 10/603,064 FILING DATE: June 24, 2003 GROUP: 1653
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C22	Y-H Ding et al., "Zinc-Dependent Dimers Observed in Crystals of Human Edostatin," Proceedings of the National Academy of Sciences of USA, Vol. 95, No. 18, pages 10443-10448, September 1988.
	C23	Earnest et al., "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," J. Cell. Biochem, Supp, 161: 156-166 (1992).
	C24	Eisenthal, (1990) "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," Cancer Immunol. Immunotherap. 31:342-348.
	C25	Friedman, J. M. et al., "Leptin and the regulation of body weight in mammals," Nature, Vol. 395, pp. 763-770. (October 22, 1998).
	C26	Gately et al. "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses" Annu. Rev. Immunol. 16:495-521 (1998)
	C27	Gillesen et al., "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist" Eur. J. Immunol. 25:200-206 (1995)
	C28	Gillies et al. "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," Proc. Natl. Acad. Sci. 89: 1428-1432 (1992)
	C29	Gillies et al. "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," Bioconj. Chem. 4: 230-235 (1993)
	C30	S. Gillies, et al. "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostrate and colon carcinoma metastases," J. Immunol., vol 160, no. 12, 15 June 1998, pages 6195-6203.
	C31	S.D. Gillies, et al: "Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors." Cancer Research. (1999 May 1) 59 (9) pages 2159-2166. JOURNAL CODE: CNF. ISSN: 0008-5472., XP002107035
	C32	Gillis et al. (1978) "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," J. of Immunol. 6:2027-2032.
	C33	E.Y. Gren et al., "A New Type of Leukocytic Interferon". 1983. Dokl. Biochem. 269: 91-95.
	C34	Guyre et al., "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> 45: 146-148 (1997).
	C35	E.T. Harvill, et al. "In vivo properties of an IgG3-IL-2 fusion protein: A gneral strategy for immune potentiation." J. Immunol. (1996 October 1) 157 (7) pages 3165-3170. JOURNAL CODE: IFB. ISSN: 0022-1767., XP002107033.
	C36	Hazama et al. "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," Vaccine 11: 629-636 (1993)
EXAMINER		DATE CONSIDERED

FORM PTO - 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003	GROUP: 1653
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C37	He et al. (1998) "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," J. Immunol. 1029-1035.	
	C38	Heinzel et al. "In Vivo Production and Function of IL-12 p40 Homodimers" In Vivo Biology of IL-12 p40 Homodimer, 4381-4388 (1997)	
	C39	Hohenester et al., "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1/5 Å Resolution", EMBO Journal, Vol. 17, No. 6, pages 1656-1664, 1998.	
	C40	Hoogenboom et al., "Constriction and expression of antibody-tumor necrosis factor fusion proteins," Molecular Immunology, Vol. 28, No. 9, 1027-1037 (1991).	
	C41	Huck et al. (1986) "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," Nucleic Acids Research 14:1779-1789.	
	C42	Huse et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281.	
	C43	Ingber et al. (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," Nature 348:555-557.	
	C44	Jones et al., (1986) "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature 321:522-525.	
	C45	Jungmans et al. (1996) "The protection receptor of IgG catabolism is the B2-microglobulin-containing neonatal intestinal transport receptor," Proc. Natl. Acad. Sci. USA 93:5512-5516.	
	C46	Kang et al. (1991) "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," Proc. Natl. Acad. Sci. USA 88:11120-11123.	
	C47	Kappel, et al. (1992) Current Opinion in Biotechnology 3:548-553	
	C48	Kendra et al., "Pharmacokinetics and stability of the ch 14.18-interleukin-2 fusion protein in mice," <u>Cancer Immunol. Immunother.</u> , 48: 219-229 (1999)	
	C49	T. Kim, et al., "An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production." J. Immunol., vol. 158, no. 9, 1 May 1997, pages 4137-4144.	
	C50	LaVallie et al. (1993) "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," J. of Biological Chemistry 268:23311-23317.	
	C51	LeBerthon et al. (1991) "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate" Cancer Research 51:2694-2698	
	C52	G. Lieschke, et al.: "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo." Nature Biotechnology, vol. 15, no. 1, January 1997, pages 35-40.	
EXAMINER		DATE CONSIDERED	

FORM PTO - 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003	GROUP: 1653
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C53	Linsley et al. (1991) "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," J. Exp. Med. 174; 561-569.	
	C54	Lo et al., "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells". XP-002143888. (1998). Protein Engineering 11: 495-500.	
	C55	Lode et al. <i>Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins</i> . Immunological Investigations 2000, Vol. 29, No. 2, pages 117-120.	
	C56	Lode et al. (1998) "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," Blood 91:1706-1715.	
	C57	Lode et al., "Synergy between an antiangiogenic integrin α_v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," Proc. Natl. Acad. Sci. USA 96:1591-1596 (1999).	
	C58	Lode et al., "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," 96:8591-8596 (1999).	
	C59	Maloney et al. (1994) "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," Blood 84:2457-2466.	
	C60	Martinotti et al. "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," Eur. J. Immunol. 25: 137-146 (1995)	
	C61	M. Mark, et al.: "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins." J. Biol. Chem., vol 267, no.36 25 December 1992, pages 26166-26171.	
	C62	Medesan et al. (1997) "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1 ¹ ," J. Immunol. 12211-2217.	
	C63	Mestre et al. (1997) "Retinoids Suppress Epidermal Growth Factor-induced Transcription of cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," Cancer Research 57:2890-2895.	
	C64	Mosmann and Coffman, "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," Ann. Rev. Immunol. 7: 145-173 (1989)	
	C65	O'Reilly et al. (1994) "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell 79:315-328.	
	C66	O'Reilly et al. (1996) "Angiostatin induces and sustains dormancy of human primary tumors in mice," Nature Medicine 2(6):689-692.	
	C67	O'Reilly et al. (1997) "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell 88:277-285.	
EXAMINER		DATE CONSIDERED	

FORM PTO - 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003	GROUP: 1653
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C68	Perez et al. (1989) "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," J. Immunol. 142:3662-3667.	
	C69	Putzer et al. "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," Proc. Nat'l Acad. Sci. 94: 10889-10894 (1997)	
	C70	Reisfeld et al. <i>Immunocytokines: a new approach to immunotherapy of melanoma</i> . Melanoma Research 1997, Vol. 7. Suppl. 2, pages S99-S106.	
	C71	Reisfeld, et al.: "Recombinant antibody fusion proteins for cancer immunotherapy." Current Topics in Microbiology and Immunology, (1996) 213 (PT 3) pages 27-53. REF: 67 JOURNAL CODE; DWQ.ISSN:0070-217X., XP002107034	
	C72	Riethmuller et al. (1994) "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," The Lancet 343:1177-1183.	
	C73	Sasaki et al. (1998) "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," The EMBO Journal 17(15):4249-4256.	
	C74	Schoenhaut et al. "Cloning and Expression of Murine IL-12," J. Immunol. 148: 3433-3340 (1992)	
	C75	Shiff et al., "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," J. Clin. Invest. 96:491-503 (1995).	
	C76	Sim et al. (1997) "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," Cancer Research 57:1329-1334.	
	C77	Stevenson et al. (1997) "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab'γ and Analogous Ligands," J. of Immunology, Vol. 158, pages 2242-2250.	
	C78	Tao et al. (1993) "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," J. Exp. Med. 178: 661-667.	
	C79	Teicher et al., (1994) "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents", Int. J. Cancer, 57, 920-925.	
	C80	<u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 th ed. 1999).	
	C81	Trinchieri, "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," Blood 84: 4008-4027 (1994)	
	C82	Vagliani et al. "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," Cancer Res. 56: 467-470 (1996)	
EXAMINER		DATE CONSIDERED	

FORM PTO - 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003	GROUP: 1653
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C83	Varki et al. (1984) "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," Cancer Research 44:681-687.	
	C84	Verhoeven et al. (1988) "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science 239:1534-1536.	
	C85	Wooley et al. (1993) "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice," J. Immunol. 151: 6602-6607.	
	C86	Wu et al., "Suppression of Tumor Growth with Recombinant Murine Angiostatin", Biochemical and Biophysical Research Communications, US, Academic Press Inc., Vol. 236, no. 3, July 30, 1997, pp. 651-654.	
	C87	Xiang et al. (1997) "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," Cancer Research 57:4948-4955.	
	C88	Xin Xau Zheng, et al: "Administration of nonstolytic IL-10/Fc in muring models of lipopolysaccaride-induced septic shock and allogenic islet transplantation." J. Immunol., 1995, 154(10), pages 5590-5600 CODEN: JOIMA3; ISSN; 0022-1767, XP002082460.	
	C89	Baselga, et al (1998) "Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor activity of Paclitazal and Doxorubicin against HER3/neu Overexpressing Human Breast Cancer Xenografts." Cancer Research 58:2825-2831.	
	C90	Holden, et al. (2001) "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents." Proceedings of the American Association for Cancer Research, vol. 42, p. 683.	
	C91	Holden, et al. (2001) "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents" Clinical Cancer Research; vol. 7, no. 9, pp. 2862-2869.	
	C92	Kim, et al. (1999) "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV" Journal of Interferon and Cytokine Research 19:77-84.	
	C93	Rozwarski, et al. (1994) "Structural comparisons among the short-chain helical cytokines" Structure 2: 159-173.	
	C94	Kuo, et al. (2001) "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," J. Cell Bio. 152:1233-1246.	
	C95	Afonso et al., (1994) "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," Science, 263:235-237.	
	C96	Becker et al., (1996) "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," Proc. Natl. Acad. Sci., 93:7826-7831.	
	C97	Buchli et al., (1993) "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," Archives of Biochemistry and Biophysics, 307:411-415.	
EXAMINER		DATE CONSIDERED	

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003 GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C98	Chang et al., (1996) "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271:13349-13355.	
	C99	Collins et al., (1988) "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci.</u> , 85:7709-7713.	
	C100	Hellström et al., (1986) "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci.</u> , 83:7059-7063.	
	C101	Hu et al., (1996) "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.	
	C102	Ju et al., (1987) "Structure-Function Analysis of Human Interleukin-2," <u>Journal of Biological Chemistry</u> , 262:5723-5731.	
	C103	Mott et al., (1995) "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994.	
	C104	Roessler et al., (1994) "Cooperative Interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-binding affinity of the receptor subunits," <u>Proc. Natl. Acad. Sci.</u> , 91:3344-3347.	
	C105	Sauve et al., (1991) "Localization in human interleukin 2 of the binding site of the α chain (p55) of the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 88:4636-4640.	
	C106	Senter et al., (1988) "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <u>Proc. Natl. Acad. Sci.</u> , 85:4842-4846.	
	C107	Shanafelt et al., (2000) "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," <u>Nature Biotechnology</u> , 18:1197-1202.	
	C108	Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30(1):105-108.	
	C109	Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Molecular Immunology</u> , 30(4):379-386.	
	C110	Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <u>J. Clin. Invest.</u> , 98(12):2801-2804.	
	C111	Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <u>J. Exp. Med.</u> , 183(50):2361-2366.	
	C112	Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher (ed.), pp. 175-193.	
	C113	Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.	
EXAMINER		DATE CONSIDERED	

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003	GROUP: 1653
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C114	Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," <u>The Journal of Biological Chemistry</u> , 268(21):15983-15993.	
	C115	Briggs et al., (1974), "Hepatic Clearance of Intact and Desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227(6):1385-1388.	
	C116	Caton et al., (1986), "Structural and Functional Implications of a Restricted Antibody Response to a Defined Antigenic Region on the Influenza Virus Hemagglutinin," <u>The EMBO Journal</u> , 5(7):1577-1587.	
	C117	Chuang et al., (1993), "Effect of New Investigational Drug Taxol on Oncolytic Activity and Stimulation of Human Lymphocytes," <u>Gynecologic Oncology</u> , 49:291-298.	
	C118	Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.	
	C119	Cruse et al., (eds.), (1995), <u>Illustrated Dictionary of Immunology</u> , pp.156-157, CRC Press, NY.	
	C120	Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.	
	C121	Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308.	
	C122	Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin. Cancer Research</u> , 4(10):2551-2557.	
	C123	Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740.	
	C124	Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16(Suppl 3):3-13.	
	C125	Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.	
	C126	Fell et al., (1992), "Chimeric L6 Anti-tumor Antibody: Genomic Construction, Expression, and Characterization of the Antigen Binding Site," <u>J. Biological Chemistry</u> , 267:15552-15558.	
	C127	Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85(5):1229-1236.	
	C128	Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80(2):317-333.	
	C129	Gan et al., (1999), "Specific Enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clinical and Diagnostic Laboratory Immunology</u> , 6(2):236-42.	
EXAMINER		DATE CONSIDERED	

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003 GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C130	Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56.	
	C131	Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60.	
	C132	Gillies et al., (2002), "Improved Circulating Half-life and Efficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Research</u> , 8(1):210-216.	
	C133	Greene et al., (1975), "Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927.	
	C134	Griffon-Etienne et al., (1999), "Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications," <u>Cancer Research</u> , 59:3776-3782.	
	C135	Hammerling et al., (1996), "In Vitro Bioassay for Human Erythropoietin Based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Carbohydrate-dependent Microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469.	
	C136	Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Research</u> , 2(12):1951-1959.	
	C137	Hank et al., (2003), "Determination of Peak Serum Levels and Immune Response to the Humanized Anti-ganglioside Antibody-interleukin-2 Immunocytokine," in <u>Methods in Molecular Medicine, Vol. 85: Novel Anticancer Drug Protocols</u> , Buolamwini et al., (eds.), pp. 123-131, Humana Press Inc., Totowana, NJ.	
	C138	Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-10459.	
	C139	Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <u>J. Chromatography A</u> , 705:129-134.	
	C140	Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds Fc γ RI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotechnology</u> , 1:95-105.	
	C141	Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human Fc γ RI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97(2):331-338.	
	C142	Hezareh et al., (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virology</u> , 75(24):12161-12168.	
	C143	Hornick et al., (1999), "Pretreatment with a Monoclonal Antibody/Interleukin-2 Fusion Protein Directed Against DNA Enhances the Delivery of Therapeutic Molecules to Solid Tumors," <u>Clin. Cancer Research</u> , 5:51-60.	
EXAMINER		DATE CONSIDERED	

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003 GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C144	Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164(8):4178-4184.	
	C145	Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Research</u> , 61(4):1500-7.	
	C146	Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527.	
	C147	Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26(2):126-131.	
	C148	Kitamura et al., (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334.	
	C149	Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma," <u>J. Clinical Oncology</u> , 19(22):4189-94.	
	C150	Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 92(10):3730-3736.	
	C151	Locatelli et al., (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104.	
	C152	Lode et al., (1997), "Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J. Natl. Cancer Inst.</u> , 89(21):1586-94.	
	C153	Lode et al., (1998), "Immunocytokines: A Promising Approach to Cancer Immunotherapy," <u>Pharmacol. Ther.</u> , 80(3):277-292.	
	C154	Lode et al., (2000), "What To Do With Targeted IL-2," <u>Drugs of Today</u> , 36(5):321-336.	
	C155	Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30.	
	C156	Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17(Supp 5):66-70.	
	C157	Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73.	
	C158	Mueller et al., (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452.	
EXAMINER		DATE CONSIDERED	

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003 GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C159	Mullins et al., (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28.	
	C160	Mullins et al., (1998), "Interleukin-12 Overcomes Paclitaxel-mediated Suppression of T-cell Proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20(4):473-492.	
	C161	Naramura et al., (1994), "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein Against Human Melanoma Cells," <u>Immunology Letters</u> , 39:91-99.	
	C162	Neal et al., (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol. Immunother.</u> , 53:41-52.	
	C163	Netti et al., (1995), "Time-dependent Behavior of Interstitial Fluid Pressure in Solid Tumors: Implications for Drug Delivery," <u>Cancer Research</u> , 55:5451-5458.	
	C164	Netti et al., (1999), "Enhancement of Fluid Filtration Across Tumor Vessels: Implication for Delivery of Macromolecules," <u>Proc. Nat. Acad. Sci. USA</u> , 96:3137-3142.	
	C165	Ngo et al., (1994), "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz et al. (eds.), pp. 433-440 and 492-495, Birkhauser, Boston, MA.	
	C166	Niethammer et al., (2002) "An Oral DNA Vaccine Against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-429.	
	C167	Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma," <u>Cancer Research</u> , 61(16):6178-84.	
	C168	Nimtze et al., (1993), "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56.	
	C169	Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92.	
	C170	Park et al., (2000), "Efficiency of Promoter and Cell Line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172.	
	C171	Polizzi et al., (1999), "A Novel Taxane with Improved Tolerability and Therapeutic Activity in a Panel of Human Tumor Xenografts," <u>Cancer Research</u> , 59:1036-1040.	
	C172	Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J. Clin. Lab. Anal.</u> , 10:160-166.	
EXAMINER		DATE CONSIDERED	

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003 GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C173	Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic <i>nu/nu</i> Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Research</u> , 56(8):1707-1712.	
	C174	Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , 3 rd Ed., pp. 8.3-8.4.	
	C175	Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Research</u> , 61(23):8498-503.	
	C176	Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30.	
	C177	Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of Controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93(16):1204-1214.	
	C178	Sharma et al., (1999), "T cell-derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T cell and APC Function," <u>Journal of Immunology</u> , 163:5020-5028.	
	C179	Shinkawa et al., (2003), "The Absence of Fucose But Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473.	
	C180	Spiekermann et al., (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310.	
	C181	Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," Chapter 36, pp. 451-456, in <u>Therapeutic Immunology</u> , Austen et al., (eds.), Blackwell Science.	
	C182	Sulitzeanu, (1993), "Immunosuppressive Factors in Human Cancer," pp. 247-266 in <u>Advances in Cancer Research</u> , Vol. 60, Vande Woude et al. (eds.), Academic Press, Inc.	
	C183	Syed et al., (1998), "Efficiency of Signaling Through Cytokine Receptors Depends Critically on Receptor Orientation," <u>Nature</u> , 395:511-516.	
	C184	Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004.	
	C185	Villunger et al., (1997), "Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-induced Suppression of Immune Surveillance," <u>Blood</u> , 90(1):12-20.	
	C186	Watanabe et al., (1997), "Long-term Depletion of Naive T cells in Patients Treated for Hodgkin's Disease," <u>Blood</u> , 90(9):3662-3672.	
EXAMINER		DATE CONSIDERED	

FORM PTO – 1449		ATTY DOCKET NO.: LEX-010C1	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT: Gillies et al.	
		SERIAL NO.: 10/603,064	
		FILING DATE: June 24, 2003 GROUP: 1653	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C187	Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.	
	C188	Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82(5):1507-1516.	
	C189	Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925.	
	C190	Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunology</u> , 163(7):3676-83.	
	C191	Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J. Immunology</u> , 167(8):4560-5.	
	C192	Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clinical Cancer Research</u> , 7(3 Supp):S856-S864.	
	C193	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269(5):3469-3474.	
	C194	Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clinical Oncology</u> , 16(6):2169-80.	
	C195	Zagozdzon et al., (1999), "Potentiation of Antitumor Effects of IL-12 in Combination with Paclitaxel in Murine Melanoma Model <i>In Vivo</i> ," <u>International Journal of Molecular Medicine</u> , 4:645-648.	
EXAMINER		DATE CONSIDERED	

3037071